A pioneering study from the newly established Brain Tumour Research Centre of Excellence at the University of Nottingham aims to predict early recurrence of brain cancer, specifically glioblastoma. By integrating advanced brain imaging scans taken during surgery with genomic analyses of cancer cells at the infiltrative margin, researchers are set to harness artificial intelligence and mathematical modeling to provide individualized predictions for tumor recurrence.
This innovative approach will target the infiltrative margin, where glioblastoma’s biology closely resembles that of recurring tumors, rather than the original tumor itself. The research team plans to identify potential drug targets within this crucial area, facilitating earlier targeted treatments post-surgery, even before conventional imaging scans detect any signs of recurrence. The researchers anticipate initiating clinical trials employing this method within the next five years.
The announcement has been met with optimism from individuals affected by glioblastoma. Verity Phillips, a 35-year-old mother of four from Lincolnshire, was diagnosed with glioblastoma in 2022 after experiencing a collapse. She reflects on her challenging journey: “Glioblastoma is brutal. Like most people diagnosed, I was given just 12 to 18 months to live. I’ve already beaten those odds, but I live from scan to scan, wondering how long I’ll be ‘lucky’ for.”
Verity emphasizes the need for increased funding and research: “We need more funding for more research now so that there are better treatments for all the mums who follow; for all those who will hear the words, ‘You have brain cancer’. The Nottingham Centre will be a beacon of hope to glioblastoma patients like me.”
Urgent Need for Research Funding
Brain tumors are particularly indiscriminate, affecting individuals under 40 more than any other cancer type. Alarmingly, only 1% of national cancer research funding has been allocated to brain tumors since records began in 2002. Dan Knowles, CEO of Brain Tumour Research, highlights the urgency of supporting research efforts: “Brain Tumour Research, our supporters, and the broader community are driven by the need to ensure that, in the future, no other family is forced to face this awful disease.”
Knowles expresses confidence in the progress being made: “We are on the cusp of change – and this new Brain Tumour Research Centre of Excellence at the University of Nottingham will play a pivotal role in delivering cutting-edge research to bring about the cure that is so desperately needed.”
As the research team at the University of Nottingham embarks on this groundbreaking study, the hope is that their work will not only improve individual patient outcomes but also contribute to the wider fight against this devastating disease. The integration of advanced imaging and genomic analysis represents a significant step forward in understanding and combating glioblastoma, potentially transforming patient care and treatment strategies in the years to come.
